1[1]Leibson PJ.Signal transduction during natural killer cell activation:inside the mind of a killer.Immunity,1997,6:655-661.
2[2]Diefenbach A,Raulet DH.Innate immune recognition by stimulatory immunoreceptors.Curr Opin Immunol,2003,15(1):37-44.
3[3]Jamieson AM,Diefenbach A,McMahon CW,et al.The role of the NKG2D immunoreceptor in immune cell activation and natural killing.Immunity,2002,17(1):19-29.
4[4]Watson NF,Spendlove I,Madjd Z,et al.Expression of the stressrelated MHC class I chain-related prote in MICA is an indicator of good prognosis in colorectal cancer patients.Int J Canceg,2006,118(6):1445-1452.
5[5]Raffaghello L,Prigione I,Airoldi I,et al.Downregulation and/or rdease of NKG2D ligands as imanune evasion strategy of human neuroblastoma.Neoplasia,2004,6(5):558-568.
6[6]Groh V,Wu J,Yee C,et al.Turnout-derived solubh MIC ligands impair expression of NKG2D and T-cell activation.Nature,2002,419(6908):734-738.
7[7]Cerwenka A.Lanier LL.NKG2D ligands:unconventional MHC class I-like molecules exploited by viruses and cancer.Tissue Antigens,2003,61(5):335-343.
2Mizutani K, Terasaki P, Bignon JD, Hourmant M, Cesbron-Gautier A, Shih RN, Pei R, Lee J, Ozawa M. Association of kidney transplant failure and antibodies against MICA.Hum Immunol 2006; 67: 683-691.
3Ahmad T, Marshall SE, Mulcahy-Hawes K, Orchard T, Crawshaw J, Armuzzi A, Neville M, van Heel D, Bamardo M, Welsh KI, Jewell DP, Bunce M. High resolution MIC genotyping: design and application to the investigation of inflammatory bowel disease susceptibility. Tissue Antigens 2002; 60:164-179.
4Holmes MA, Li P, Petersdorf EW, Strong RK. Structural studies of allelic diversity of the MHC class I homolog MIC-B, a stress-inducible ligand for the activating immunoreceptor NKG2D. J Immunol 2002; 169:1395-1400.
5Radosavljevic M, Cuillerier B, Wilson MJ, Clement O, Wicker S, Gilfillan S, Beck S, Trowsdale J, Bahram S. A cluster of ten novel MHC class Ⅰ related genes on human chromosome 6q24.2-q25.3. Genomics 2002; 79:114-123.
6Chalupny NJ, Sutherland CL, Lawrence WA, ReinWeston A, Cosman D. ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun 2003; 305:129-135.
7Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008; 27:5944-5958.
8Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, Raulet DH. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008; 28:571-580.
9Zompi S, Hamerman JA, Ogasawara K, Schweighoffer E, Tybulewicz VL, Di Santo JP, Lanier LL, Colucci F. NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases. Nat Immunol 2003; 4:565-572.
10Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D. UL16-binding proteins, novel MHC class Ⅰ-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. Jlmmunol 2002; 168:671-679.
